Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.63 |
| ▸ | ECE1 | P42892 | 1/20 | 0.63 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30627035 | 0.97 | RXFP1 (0.66) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL30874400 | 0.97 | RXFP1 (0.62) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL29373303 | 0.96 | GLP1R (0.65) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL30220493 | 0.94 | RXFP1 (0.65) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL30598132 | 0.93 | RXFP1 (0.64) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL31087271 | 0.93 | RXFP1 (0.68) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL30271994 | 0.93 | RXFP1 (0.68) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL30637763 | 0.93 | RXFP1 (0.61) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL31759108 | 0.91 | RXFP1 (0.67) | GLP1RECE1MUS81RXFP1NPBWR1 | |
| SCHEMBL31453802 | 0.91 | GLP1R (0.72) | GLP1RECE1MUS81RXFP1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | claimed |
| EP-4380962-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN Laboratories Private Limited, R&D Center (IN) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012829-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-09 | — | — | WO | claimed |
| CN-110615836-B | Solid-phase synthesis method of liraglutide | 鲁南制药集团股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| CN-119178830-A | Analysis method for determining impurity content of liraglutide | 深圳市健元医药科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-4380962-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN Laboratories Private Limited, R&D Center (IN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-116836258-A | Solid phase synthesis method of liraglutide | 辽宁药联制药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116410297-A | Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof | 内蒙古博睿精创科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023012829-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | GLP1R, IAPP, GCG | GLP1R 1/4885ECE1 2143/4885MUS81 2889/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | GLP1R 1/4885ECE1 1694/4885MUS81 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.